01 Emergence of Triple Artemisinin-Based Combination Therapies (TACTs)A major trend in the artemisinin combination therapy market is the growing focus on triple artemisinin-based combination therapies (TACTs) to overcome emerging resistance to traditional ACTs. Researchers and pharmaceutical companies are developing formulations that combine an artemisinin derivative with two partner drugs to enhance efficacy and delay resistance. Clinical studies supported by the Mahidol Oxford Tropical Medicine Research Unit showed that triple combinations such as artemether lumefantrine amodiaquine improved treatment outcomes in multidrug-resistant malaria regions. This advancement is expected to redefine malaria treatment protocols, particularly in high-burden countries.
02 Expansion of WHO Prequalified Manufacturing and Local Production InitiativesThe major trend is the expansion of WHO prequalified ACT manufacturing in endemic regions to strengthen drug availability and supply chain stability. Local production initiatives in Africa and Southeast Asia are reducing dependency on imported medicines while ensuring consistent quality and affordability. For instance, partnerships between international health agencies and regional producers have led to the establishment of GMP-certified facilities capable of large-scale ACT production, aligning with global malaria elimination strategies.
01 Increasing Pediatric Formulation DevelopmentThe artemisinin combination therapy market is being driven by the increasing focus on developing pediatric-friendly formulations that enhance treatment accessibility and adherence among children in malaria-endemic regions. Companies are prioritizing age-appropriate dosage forms such as granules, syrups, and dispersible tablets to ensure easier administration and accurate dosing for young patients. For instance, Cipla introduced pediatric formulations of artemether lumefantrine tailored for children under five years of age, improving compliance and clinical outcomes. This growing emphasis on child-specific therapies is expanding treatment coverage, supporting early intervention programs, and contributing to global malaria reduction effort.
01 Supply Chain Vulnerabilities and Limited Cold Chain InfrastructureThe artemisinin combination therapy market faces challenges due to persistent supply chain inefficiencies and inadequate cold chain infrastructure, particularly in low and middle income countries. Fluctuations in raw material availability, dependency on seasonal cultivation of Artemisia annua, and logistical barriers often leads to inconsistent drug supply and delayed distribution. Several African and Southeast Asian nations reported disruptions in the delivery of artemisinin-based medicines due to limited temperature controlled storage and transportation systems. These supply chain constraints hindered timely access to essential antimalarial therapies, increased production costs, and pose a major obstacle to maintaining continuous treatment availability in high-burden regions.
01 Development of Fixed Dose CombinationsThe development of fixed-dose artemisinin combinations presents a major opportunity for enhancing treatment adherence and expanding market reach. Fixed dose formulations simplify dosing regimens by combining multiple active ingredients into a single tablet, improving patient compliance and minimizing the risk of drug resistance. For instance, Novartis and Ipca Laboratories invested in the development of optimized fixed-dose artemether-lumefantrine and artesunate-amodiaquine combinations to support large-scale malaria elimination initiatives. These advancements streamlined manufacturing, reduced distribution complexities, and strengthened the therapeutic value of ACTs in both public and private healthcare programs globally.
June 2026 Novartis expanded its malaria treatment portfolio by advancing Artemisinin Combination Therapy (ACT) solutions through improved formulations, supply chain initiatives, and access programs. The company focused on strengthening malaria treatment availability, improving patient outcomes, and supporting global efforts to reduce malaria burden.
April 2026 Sanofi expanded its infectious disease portfolio by strengthening malaria treatment initiatives, including research and development efforts focused on improving antimalarial therapies and supporting access to effective combination treatments in malaria-endemic regions.
January 2026 Cipla expanded its anti-infective pharmaceutical portfolio by enhancing its artemisinin-based combination therapy offerings. The company focused on improving availability of affordable malaria treatments and supporting healthcare programs in developing regions.
October 2025 Guilin Pharmaceutical expanded its antimalarial drug portfolio by improving production capabilities and distribution networks for artemisinin-based combination therapies. The company focused on supporting global malaria control programs through reliable treatment supply.